Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 4, Number 1—March 1998

Synopsis

Proteases of Malaria Parasites: New Targets for Chemotherapy

Philip J. RosenthalComments to Author 
Author affiliation: San Francisco General Hospital and University of California, San Francisco, California, USA

Main Article

Table 2

New antimalarial drugs

Drug Role Best Feature(s) Limitations
Halofantrine TX of Pf malaria; not approved for CP Usually effective against R Pf malaria Variable bioavailability, cardiac toxicity
Artemisinin and related compoundsa TX of Pf malaria Rapidly acting; effective against multidrug-R strains Recurrence after TX fairly common
Atovaquone ? TX of Pf malaria; ? CP (probably in combination with proguanil) Limited toxicity Limited studies so far show frequent recurrence after TX
Pyronaridinea ? TX of Pf malaria Effective against R strains Studies limited to date
Desferrioxamine ? TX of severe Pf malaria Well tolerated when used for iron overload Studies limited to date
Azithromycin ? CP Limited toxicity Studies limited to date

For abbreviations, see Table 1, footnote a.
aNot available in the United States.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO